Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
HIV Dominance | Gilead's HIV franchise remains strong, with lenacapavir showing promise as a long-acting PrEP option, potentially driving market share growth and patient adherence |
Oncology Expansion | Explore Gilead's strategic push into oncology, led by Trodelvy and innovative CAR-T therapies, positioning the company for growth in a competitive market |
Financial Outlook | Delve into Gilead's solid financial performance, with analysts projecting $28.3 billion in revenues for 2024 and an average price target range of $72-$110 |
Market Challenges | Learn about Gilead's strategies to navigate patent expirations, pricing pressures, and fierce competition in key therapeutic areas while maintaining market leadership |
Metrics to compare | GILD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGILDPeersSector | |
---|---|---|---|---|
P/E Ratio | 21.4x | −2.5x | −0.5x | |
PEG Ratio | 0.02 | 0.04 | 0.00 | |
Price/Book | 6.7x | 1.0x | 2.6x | |
Price / LTM Sales | 4.4x | 53.4x | 2.9x | |
Upside (Analyst Target) | 13.9% | 273.8% | 49.4% | |
Fair Value Upside | Unlock | −0.5% | 8.2% | Unlock |